NVNO vs. ARAY, UTMD, OBIO, PROF, SKIN, BWAY, KRMD, NVRO, INFU, and TLSI
Should you be buying enVVeno Medical stock or one of its competitors? The main competitors of enVVeno Medical include Accuray (ARAY), Utah Medical Products (UTMD), Orchestra BioMed (OBIO), Profound Medical (PROF), Beauty Health (SKIN), BrainsWay (BWAY), KORU Medical Systems (KRMD), Nevro (NVRO), InfuSystem (INFU), and TriSalus Life Sciences (TLSI). These companies are all part of the "surgical & medical instruments" industry.
enVVeno Medical vs.
Accuray (NASDAQ:ARAY) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
64.1% of Accuray shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 4.2% of Accuray shares are held by insiders. Comparatively, 16.0% of enVVeno Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Accuray presently has a consensus price target of $9.00, suggesting a potential upside of 287.93%. Given Accuray's stronger consensus rating and higher possible upside, research analysts plainly believe Accuray is more favorable than enVVeno Medical.
Accuray has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
enVVeno Medical has a net margin of 0.00% compared to Accuray's net margin of -3.72%. Accuray's return on equity of -36.93% beat enVVeno Medical's return on equity.
Accuray received 176 more outperform votes than enVVeno Medical when rated by MarketBeat users. Likewise, 65.61% of users gave Accuray an outperform vote while only 62.65% of users gave enVVeno Medical an outperform vote.
Accuray has higher revenue and earnings than enVVeno Medical. Accuray is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Accuray had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 3 mentions for Accuray and 1 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 1.89 beat Accuray's score of 0.38 indicating that enVVeno Medical is being referred to more favorably in the news media.
Summary
Accuray beats enVVeno Medical on 13 of the 17 factors compared between the two stocks.
Get enVVeno Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVNO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
enVVeno Medical Competitors List
Related Companies and Tools
This page (NASDAQ:NVNO) was last updated on 1/31/2025 by MarketBeat.com Staff
